Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Iron Horse Diagnostics announces license agreement with Euroimmun to market ALS diagnostic test

Published 20 July 2016

Iron Horse Dx announced that they have signed a nonexclusive license agreement with Euroimmun Medizinische Labordiagnostika AG (Lübeck, Germany) to launch the first biological diagnostic test for amyotrophic lateral sclerosis (“ALS”), more commonly known as Lou Gehrig’s disease.

ALS is a progressive neurological disease with an average life span of 3-5 years from diagnosis. Current clinical methods to diagnose ALS can take over one year, leaving patients helpless to act during the early stages of the disease and limiting their ability to join clinical trials of newer disease modifying therapeutics in drug development.

The ALS Test is based on over 20 years of research by Dr. Robert Bowser, President of Iron Horse Dx, and is shown to be 93% accurate (positive predictive value = 0.939 and negative predictive value = 0.917), providing a first biological based diagnostic test for ALS.

According to Dr. Bowser, “We have come a long way in researching and understanding the complexities of ALS over the past few years. The ALS Test will benefit patients by aiding physicians to make a more rapid and definitive diagnosis, allowing more efficient clinical trials in particular in early phases of ALS, thereby shorting the time to finding a cure.”

Under the terms of the license agreement, Euroimmun AG, with over 2,100 employees worldwide and distribution into over 130 countries, will have the nonexclusive rights to launch the ALS diagnostic assays as a CE marked product, while Iron Horse is launching the assay in the U.S. as a laboratory-developed test in CLIA-certified laboratories.

Iron Horse is working in close collaboration with the ALS Association (ALSA) and has received funding from the National Institutes of Health, Biogen and the state of Arizona.

According to Dr. Winfried Stöcker, President and Managing Director of Euroimmun, “Euroimmun has extensive expertise in the fields of neuroimmunology.

“Together with Iron Horse Dx, we were able to develop this novel CE-marked assay for neurofilament heavy chain, complementing our portfolio of neurological diagnostics. With the launch next month, the test will be distributed worldwide to reach as many people as possible with this devastating disease.”

Iron Horse Dx was formed to create breakthrough diagnostic tests in neurologic disorders with high-unmet medical need. The company was founded in 2012 and has received funding from The National Institutes of Health, The ALS Association, The Arizona Commerce Authority and Biogen to finalize development and commercialize the ALS Test.

EUROIMMUN AG produces test systems and automation solutions for medical laboratory diagnostics.



Source: Company Press Release